Jeffrey J. Molldrem

Dr. Jeffrey J. Molldrem


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2003 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JMJeffrey J. Molldrem
Jeffrey J. Molldrem
PLPeter P. Lee
Peter P. Lee
SKShreya Kant
Shreya Kant
EWEric Wieder
Eric Wieder
WJWeidong Jiang
Weidong Jiang
MDMark M. Davis
Mark M. Davis
We have shown that cytotoxic T lymphocytes specific for PR1, an HLA-A2–restricted nonopeptide derived from proteinase 3, kill leukemia cells and may contribute to the elimination of chronic myelogenous leukemia (CML) after treatment with IFN or allogeneic bone marrow transplant. Some patients with persistent disease also have circulating PR1-specific T cells, however, suggesting the likelihood of immune tolerance. Here we show that both high- and low-avidity PR1-specific T cells from the peripheral blood of healthy donors can be identified and selectively expanded in vitro. Although high-avidity PR1-specific T cells killed CML more effectively than low-avidity T cells, only high-avidity T cells underwent apoptosis when stimulated with high PR1 peptide concentration or when exposed to leukemia that overexpressed proteinase 3. No high-avidity PR1-specific T cells could be identified or expanded from newly diagnosed leukemia patients, whereas low-avidity T cells were readily expanded. Circulating high-avidity PR1-specific T cells were identified in IFN-sensitive patients in cytogenetic remission, however. These results provide evidence that CML shapes the host immune response and that leukemia outgrowth may result in part from leukemia-induced selective deletion of high-avidity PR1-specific T cells.

6 August 2002 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
JMJeffrey J. Molldrem
Jeffrey J. Molldrem
ELEric Leifer
Eric Leifer
EBErkut Bahceci
Erkut Bahceci
YSYogen Saunthararajah
Yogen Saunthararajah
MRMary Rivera
Mary Rivera
ABA. John Barrett
A. John Barrett
Almost half of the deaths that result from myelodysplastic syndromes are due to cytopenia associated with bone marrow failure. Treatment is mostly supportive care. To determine whether treatment with antithymocyte globulin improves cytopenia and reverses dependence on red blood cell transfusions in patients with myelodysplastic syndromes. Single-treatment, prospective study. Tertiary referral center. 61 patients with myelodysplastic syndromes. Antithymocyte globulin, 40 mg/kg of body weight, given daily for 4 days. Evaluation of bone marrow, blood counts, transfusions, progression, and survival for a median of 30 months (range, 1 to 88 months). Within 8 months of treatment, 21 of 61 patients (34%) no longer required red blood cell transfusions. This independence from transfusions was maintained in 17 responders (81%) for a median of 36 months (range, 3 to 72 months). Ten of 21 patients (47.5%) with severe thrombocytopenia had sustained platelet count increases, and 6 of 11 patients (55%) with severe neutropenia had sustained neutrophil counts of greater than 1 × 109 cells/L. Characteristics favorable for response were younger patient age (P = 0.005) and lower platelet counts (P = 0.038). One of the 21 responders (5%) and 22 of the 40 nonresponders (55%) died before the end of the study (P = 0.008). One of the 21 responders (5%) and 13 of the 40 nonresponders (33%) had disease progression (P = 0.086). Although this study was a nonrandomized, single-treatment study, 34% of patients treated with antithymocyte globulin became transfusion independent. Response was associated with a statistically significant longer survival and an almost significant decreased time to disease progression. Treatment with antithymocyte globulin did not seem to be detrimental because historical overall median survival times were similar to those of nonresponders.

1 August 2016 in Cytotherapy
Verified
Journal Article
Closed access
QMQing Ma
Qing Ma
HGHaven R. Garber
Haven R. Garber
SLSijie Lu
Sijie Lu
HHHong He
Hong He
ETEran Tallis
Eran Tallis
JMJeffrey J. Molldrem
Jeffrey J. Molldrem

1 July 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
EMElizabeth A. Mittendorf
Elizabeth A. Mittendorf
GAGheath Alatrash
Gheath Alatrash
NQNa Qiao
Na Qiao
YWYun Wu
Yun Wu
PSPariya Sukhumalchandra
Pariya Sukhumalchandra
JMJeffrey J. Molldrem
Jeffrey J. Molldrem
There is little understanding of the impact of tumor-associated neutrophils (TAN) on adaptive immunity to tumors. In this study, we report the results of an investigation of the pathobiologic basis for the prognostic significance of neutrophil elastase, a serine protease found in neutrophil granules, in a model of cyclin E (CCNE)–overexpressing breast cancer. We established that neutrophil elastase was expressed by TAN within breast cancer tissues but not by breast cancer cells. Neutrophil elastase modulated killing of breast cancer cells by CTLs specific for CCNE-derived HLA-A2–restricted peptide (ILLDWLMEV). Breast cancer cells exhibited striking antigen-specific uptake of neutrophil elastase from the microenvironment that was independent of neutrophil elastase enzymatic activity. Furthermore, neutrophil elastase uptake increased expression of low molecular weight forms of CCNE and enhanced susceptibility to peptide-specific CTL lysis, suggesting that CCNE peptides are naturally presented on breast cancer cells. Taken together, our findings reveal a previously unknown mechanism of antitumor adaptive immunity that links cancer cell uptake of an inflammatory mediator to an effective cytolytic response against an important breast cancer antigen. Cancer Res; 72(13); 3153–62. ©2012 AACR.

16 November 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
ZSZaker I. Schwabkey
Zaker I. Schwabkey
DWDiana H. Wiesnoski
Diana H. Wiesnoski
CCChia-Chi Chang
Chia-Chi Chang
WTWen-Bin Tsai
Wen-Bin Tsai
DPDung Pham
Dung Pham
RJRobert R. Jenq
Robert R. Jenq
Not all patients with cancer and severe neutropenia develop fever, and the fecal microbiome may play a role. In a single-center study of patients undergoing hematopoietic cell transplant ( n = 119), the fecal microbiome was characterized at onset of severe neutropenia. A total of 63 patients (53%) developed a subsequent fever, and their fecal microbiome displayed increased relative abundances of Akkermansia muciniphila , a species of mucin-degrading bacteria ( P = 0.006, corrected for multiple comparisons). Two therapies that induce neutropenia, irradiation and melphalan, similarly expanded A. muciniphila and additionally thinned the colonic mucus layer in mice. Caloric restriction of unirradiated mice also expanded A. muciniphila and thinned the colonic mucus layer. Antibiotic treatment to eradicate A. muciniphila before caloric restriction preserved colonic mucus, whereas A. muciniphila reintroduction restored mucus thinning. Caloric restriction of unirradiated mice raised colonic luminal pH and reduced acetate, propionate, and butyrate. Culturing A. muciniphila in vitro with propionate reduced utilization of mucin as well as of fucose. Treating irradiated mice with an antibiotic targeting A. muciniphila or propionate preserved the mucus layer, suppressed translocation of flagellin, reduced inflammatory cytokines in the colon, and improved thermoregulation. These results suggest that diet, metabolites, and colonic mucus link the microbiome to neutropenic fever and may guide future microbiome-based preventive strategies.

15 April 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
GAGheath Alatrash
Gheath Alatrash
NQNa Qiao
Na Qiao
MZMao Zhang
Mao Zhang
MZMadhushree Zope
Madhushree Zope
APAlexander A. Perakis
Alexander A. Perakis
EMElizabeth A. Mittendorf
Elizabeth A. Mittendorf
Purpose: Inefficient homing of adoptively transferred cytotoxic T lymphocytes (CTLs) to tumors is a major limitation to the efficacy of adoptive cellular therapy (ACT) for cancer. However, through fucosylation, a process whereby fucosyltransferases (FTs) add fucose groups to cell surface glycoproteins, this challenge may be overcome. Endogenously fucosylated CTLs and ex vivo fucosylatedcord blood stem cells and regulatory T cells were shown to preferentially home to inflamed tissues and marrow. Here we show a novel approach to enhance CTL homing to leukemic marrow and tumor tissue. Experimental Design: Using the enzyme FT-VII, we fucosylated CTLs that target the HLA-A2-restricted leukemia antigens CG1 and PR1, the HER2-derived breast cancer antigen E75, and the melanoma antigen gp-100. We performed in vitro homing assays to study the effects of fucosylation on CTL homing and target killing. We used in vivo mouse models to demonstrate the effects of ex vivo fucosylation on CTL anti-tumor activities against leukemia, breast cancer and melanoma. Results: Our data show that fucosylation increases in vitro homing and cytotoxicity of antigen specific CTLs. Furthermore, fucosylation enhances in vivo CTL homing to leukemic bone marrow, breast cancer and melanoma tissue in NOD/SCID gamma (NSG) and immunocompetent mice, ultimately boosting the anti-tumor activity of the antigen-specific CTLs. Importantly, our work demonstrates that fucosylation does not interfere with CTL specificity. Conclusions: Together, our data establish ex vivo CTL fucosylation as a novel approach to improving the efficacy of ACT, which may be of great value for the future of ACT for cancer.